10 Aug 2006

Tougher Action against Subutex Abuse, 10 August 2006

Following a review of the use of Subutex (or buprenorphine hydrochloride) as a drug to treat opiate dependence, the Ministry of Home Affairs (MHA) and the Ministry of Health (MOH) have decided to impose stringent measures to curb the abuse of Subutex:

(a) From 14 August 2006, buprenorphine, the active ingredient in Subutex, will be made a Class A Controlled Drug under the First Schedule of the Misuse of Drugs Act (MDA). The importation, distribution, possession and consumption of Subutex will be an offence unless specifically exempted by the relevant authorities. Penalties for offences under MDA are listed in Annex A.

(b) MOH will implement a Subutex Voluntary Rehabilitation Programme (SVRP) to help all those currently on Subutex wean off their dependence and to stay free from opiates. Developed by a panel of psychiatrists, SVRP consists of a medical component which would be complemented by counseling, psychosocial therapy and group support by doctors and counselors to prevent relapse. There will be a two-week period (14 - 27 August 2006) for Subutex users to sign up for the SVRP. They can do so through existing doctors managing their opiate dependence.

(c) From 14 August 2006, doctors will not be permitted to prescribe and dispense any take-home dosages for existing patients. All patients who require Subutex will have to consume their medication under direct visual observation of the pharmacist, doctor and/or his treatment team on a daily basis1 . Between 14 Aug 2006 to 27 Aug 2006, doctors who are currently treating patients who sign up for SVRP would be allowed to continue to prescribe and dispense Subutex to these patients until the day they commence their first SVRP appointment. From Aug 28, except for those who are enrolled in the SVRP, no other patient will have access to Subutex. Anyone caught in possession of Subutex without proper authorization will be prosecuted. Please refer to Annex B for more details on the SVRP. The hotline to call for the SVRP is 63258607.

Background Information on Subutex Abuse in Singapore

2. Subutex (or buprenorphine hydrochloride) was approved for use in 2000 by the Ministry of Health and introduced in 2002 as substitution treatment for opiate-dependent (i.e. heroin) drug abusers. The aim of substitution therapy is to reduce craving for heroin and facilitate improvement in social functioning such as employment and personal relationships.

3. However, drug addicts were found abusing Subutex by mixing it with other drugs and injecting the cocktail into their body. The intravenous misuse of drugs also gives rise to potential medical complications such as Hepatitis B and C, and HIV infection, and limb gangrene. Deaths have also been reported when addicts inject Subutex intravenously with other drugs. Some addicts discard the used syringes indiscriminately, causing public concern about health and safety issues. We saw the emergence of a needle culture, something which we have not seen in the past, even at the height of the heroin abuse problem.

4. To tighten control on Subutex prescription, MOH introduced the Clinical Practice Guidelines (CPG) on “Treatment of Opiate Dependence” in Nov 2005. The CPG describes good clinical practices and administrative controls to ensure appropriate prescription of Subutex. MOH also introduced the Central Addiction Registry for Drugs, Singapore (CARDS) which monitors the prescription of Subutex by doctors and enables them to identify patients who obtain additional supplies from different doctors. In addition, MOH requires Subutex-prescribing doctors to attend a mandatory 8-hour training course. Despite all the measures taken by MOH, the Subutex abuse situation on the ground persisted.

5. The Central Narcotics Bureau (CNB), in investigating into reports on the abuse of Subutex, discovered that the drug supply came primarily from licit sources. There was no known illicit supply of Subutex as there was no demand for it. Subutex could be obtained lawfully from General Practitioners. As Subutex is a licensed drug under the Medicines Act, CNB could not take action against the abusers of Subutex. Any effort to make Subutex a controlled drug must be accompanied by measures to tightly control its administration as a treatment regime. The alternative is to completely regulate and prohibit the distribution, possession and consumption of Subutex.

Singapore’s Zero Tolerance Policy

6. Our national strategy against drug abuse is based on a holistic framework with a multi-pronged approach of preventive education, tough enforcement to arrest addicts and traffickers swiftly, treatment 2and rehabilitation to reform the addicts, and aftercare to reintegrate reformed addicts back into society. In addition, we have introduced long term imprisonment and caning for recalcitrant addicts. This approach has proven successful, with addicts being clean upon release from the Drug Rehabilitation Centres. There is no easy solution to the problem of drug addiction. Beyond what the authorities can do, the individual has the responsibility of avoiding drugs knowing that it can only bring misery. Those who are addicted must be committed and determined to kick their habit.

7. In deciding on the approach to deal with the Subutex abuse problem, MHA and MOH have to ensure that current users/abusers of Subutex receive support and assistance to wean off their dependence on the drug. We have decided to take a holistic approach and make buprenorphine, the active ingredient in Subutex, a Class A Controlled Drug. It will be an offence to import, distribute, possess or consume Subutex unless specifically exempted by the relevant authorities. At the end of the SVRP, Subutex will only be available under very restrictive conditions; namely, buprenorphine will only be allowed to be used by medical specialists approved by the Director of Medical Service under stringent indications.

8. We strongly encourage all existing Subutex users to enroll for the SVRP with their existing doctors managing their opiate dependence. We urge families and friends of Subutex users to encourage them to sign up for the SVRP early and support them as they seek to re-integrate into society and lead a drug-free life.

MINISTRY OF HEALTH
MINISTRY OF HOME AFFAIRS
CENTRAL NARCOTICS BUREAU
10 AUGUST 2006

 


 

Footnote:

1If the clinic is closed during weekends or public holidays, patients will be provided with a private prescription for direct observed treatment with Subutex at designated pharmacies.

2Notably, treatment within the Drug Rehabilitation Centres has not relied on the use of any substitute drugs.


Last Updated on 15 Jun 2015
Back to top